دورية أكاديمية
Cost-effectiveness model of trastuzumab deruxtecan as second-line treatment in HER2-positive unresectable and/or metastatic breast cancer in Finland.
| العنوان: | Cost-effectiveness model of trastuzumab deruxtecan as second-line treatment in HER2-positive unresectable and/or metastatic breast cancer in Finland. |
|---|---|
| المؤلفون: | Paulissen JHJ; Department of Health Sciences, University Medical Center Groningen, Groningen, The Netherlands. j.h.j.paulissen@umcg.nl.; Asc Academics, Groningen, The Netherlands. j.h.j.paulissen@umcg.nl., Seddik AH; Daiichi Sankyo Europe GmbH, Munich, Germany., Dunton KJ; Daiichi Sankyo UK Ltd, Uxbridge, UK., Livings CJ; AstraZeneca Plc., Cambridge, UK., van Hulst M; Department of Health Sciences, University Medical Center Groningen, Groningen, The Netherlands.; Department of Clinical Pharmacy and Toxicology, Martini Hospital, Groningen, The Netherlands., Postma MJ; Department of Health Sciences, University Medical Center Groningen, Groningen, The Netherlands., de Jong LA; Department of Health Sciences, University Medical Center Groningen, Groningen, The Netherlands., Freriks RD; Asc Academics, Groningen, The Netherlands.; Department of Economics, Econometrics and Finance, Faculty of Economics & Business, University of Groningen, Groningen, The Netherlands. |
| المصدر: | The European journal of health economics : HEPAC : health economics in prevention and care [Eur J Health Econ] 2024 Jun; Vol. 25 (4), pp. 689-699. Date of Electronic Publication: 2023 Jul 24. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Springer-Verlag Country of Publication: Germany NLM ID: 101134867 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1618-7601 (Electronic) Linking ISSN: 16187598 NLM ISO Abbreviation: Eur J Health Econ Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Berlin : Springer-Verlag, c2001- |
| مواضيع طبية MeSH: | Breast Neoplasms*/drug therapy , Breast Neoplasms*/pathology , Cost-Benefit Analysis* , Trastuzumab*/therapeutic use , Trastuzumab*/economics , Quality-Adjusted Life Years* , Receptor, ErbB-2*/metabolism , Camptothecin*/analogs & derivatives , Camptothecin*/therapeutic use , Camptothecin*/economics, Humans ; Finland ; Female ; Antineoplastic Agents, Immunological/therapeutic use ; Antineoplastic Agents, Immunological/economics ; Ado-Trastuzumab Emtansine/therapeutic use ; Ado-Trastuzumab Emtansine/economics ; Survival Analysis ; Middle Aged ; Adult ; Immunoconjugates |
| مستخلص: | Objectives: Trastuzumab deruxtecan (T-DXd) was recently recommended by the Committee for Medicinal Products for Human Use as a treatment for adult patients with unresectable or metastatic HER2-positive breast cancer, who had received a prior anti-HER2-based regimen. In our study, we evaluated the cost-effectiveness of T-DXd compared with ado-trastuzumab emtansine (T-DM1) for this indication in Finland. Methods: A three-state partitioned survival analysis model was developed with a payer's perspective. Time to event data from the DESTINY-Breast03 (DB-03) trial were extrapolated over a lifetime horizon either directly-for progression-free survival and time to treatment discontinuation-or using an alternative approach utilizing long-term T-DM1 survival data and DB-03 data-for overall survival. Discount rates of 3% were applied for costs and effects. Inputs were sourced from the Medicinal Products Database from Kela, Helsinki University Hospital service price list, Finnish Medicines Agency assessments, clinical experts, and DB-03. Sensitivity analyses were performed to characterize and demonstrate parameter uncertainties in the model. Results: Total quality-adjusted life years (QALYs) and life years (LYs) gained for T-DXd compared with T-DM1 were 1.93 and 2.56, respectively. Incremental costs for T-DXd compared with T-DM1 were €106,800, resulting in an ICER of €55,360 per QALY gained and an ICER of €41,775 per LY gained. One-way sensitivity analysis showed the hazard ratio of T-DXd vs T-DM1 for OS was the most influential parameter. The probabilistic sensitivity analysis showed similar results to the base case. Conclusions: T-DXd is cost-effective based on surrogate WTP thresholds of €72,000 and €139,000 per QALY. (© 2023. The Author(s).) |
| References: | Ann Oncol. 2021 Dec;32(12):1475-1495. (PMID: 34678411) Pharm Stat. 2012 Mar-Apr;11(2):135-40. (PMID: 22323424) Value Health. 2014 Nov;17(7):A326. (PMID: 27200546) J Clin Oncol. 2013 Nov 1;31(31):3997-4013. (PMID: 24101045) Med Decis Making. 2019 Nov;39(8):926-938. (PMID: 31631772) N Engl J Med. 2022 Mar 24;386(12):1143-1154. (PMID: 35320644) Ann Oncol. 2020 Dec;31(12):1623-1649. (PMID: 32979513) J Health Econ Outcomes Res. 2015 Feb 14;2(2):147-160. (PMID: 37663587) Palliat Med. 2018 Feb;32(2):493-499. (PMID: 28895471) Br J Cancer. 2006 Sep 18;95(6):683-90. (PMID: 16967055) N Engl J Med. 2012 Nov 8;367(19):1783-91. (PMID: 23020162) Clin Breast Cancer. 2022 Jun;22(4):e488-e496. (PMID: 35067467) BJOG. 2022 Feb;129(3):336-344. (PMID: 35014160) J Palliat Med. 2016 Aug;19(8):863-9. (PMID: 27124211) Cochrane Database Syst Rev. 2014 Jun 12;(6):CD006242. (PMID: 24919460) |
| فهرسة مساهمة: | Keywords: Breast cancer; Cost-effectiveness; HER2-positive; Metastatic; Trastuzumab deruxtecan |
| المشرفين على المادة: | P188ANX8CK (Trastuzumab) EC 2.7.10.1 (Receptor, ErbB-2) 5384HK7574 (trastuzumab deruxtecan) XT3Z54Z28A (Camptothecin) 0 (Antineoplastic Agents, Immunological) SE2KH7T06F (Ado-Trastuzumab Emtansine) EC 2.7.10.1 (ERBB2 protein, human) 0 (Immunoconjugates) |
| تواريخ الأحداث: | Date Created: 20230724 Date Completed: 20240529 Latest Revision: 20240606 |
| رمز التحديث: | 20240606 |
| مُعرف محوري في PubMed: | PMC11136791 |
| DOI: | 10.1007/s10198-023-01617-3 |
| PMID: | 37486557 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 1618-7601 |
|---|---|
| DOI: | 10.1007/s10198-023-01617-3 |